Chemo Secrets From a Breast Cancer Survivor

Breast Cancer Survivors

Get Instant Access

118. Muller GW, Chen R, Huang SY, et al.: Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. BioorgMed Chem Lett 9(11):1625-1630, 1999.

119. Corral LG, Haslett PA, Muller GW, et al.: Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163(1):380-386, 1999.

120. Richardson PG, Schlossman RL, Weller E, et al.: Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100(9):3063-3067, 2002.

121. Barlogie B: Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience. Semin Hematol 40(suppl 4):33-38, 2003.

122. Rajkumar SV, Hayman SR, Lacy MQ, et al.: Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106(13):4050-4053, 2005.

123. Singal PK, Iliskovic N: Doxorubicin-induced cardiomyopathy. N Engl J Med 339(13):900-905, 1998.

124. Gottschalk PG, Dyck PJ, Kiely JM: Vinca alkaloid neuropathy: nerve biopsy studies in rats and in man. Neurology 18(9):875-882, 1968.

125. Alexanian R, Gehan E, Haut A, Saiki J, Weick J: Unmaintained remissions in multiple myeloma. Blood 51(6):1005-1011, 1978.

126. Berenson JR, Crowley JJ, Grogan TM, et al.: Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 99(9):3163-3168, 2002.

127. Shustik C, Belch A, Robinson S, et al.: Dexamethasone (dex) maintenance versus observation (obs) in patients with previously untreated multiple myeloma: a National Cancer Institute of Canada Clinical Trials Group Study: MY.7 [abstract]. Proc Am Soc Clin Oncol 23:558, 2004.

128. Fritz E, Ludwig H: Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol 11(11):1427-1436, 2000.

129. The Myeloma Trialists' Collaborative Group: Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 113(4):1020-1034, 2001.

130. Kyle RA: Multiple myeloma: review of 869 cases. Mayo Clin Proc 50(1):29-40, 1975.

131. Sezer O, Heider U, Zavrski I, Kuhne CA, Hofbauer LC: RANK ligand and osteoprotegerin in myeloma bone disease. Blood 101(6):2094-2098, 2003.

132. Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J: Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 116(2):278-290, 2002.

133. Luckman SP, Coxon FP, Ebetino FH, Russell RG, Rogers MJ: Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 13(11):1668-1678, 1998.

134. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ: Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13(4):581-589, 1998.

135. Frith JC, Monkkonen J, Auriola S, Monkkonen H, Rogers MJ: The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum 44(9):2201-2210, 2001.

136. Viereck V, Emons G, Lauck V, et al.: Bisphosphonates pamidronate and zoledronic acid stimulate osteoprote-gerin production by primary human osteoblasts. Biochem Biophys Res Commun 291(3):680-686, 2002.

137. Berenson JR, Lichtenstein A, Porter L, et al.: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 334(8):488-493, 1996.

138. Berenson JR, Lichtenstein A, Porter L, et al.: Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 16(2):593-602, 1998.

139. Rosen LS, Gordon D, Kaminski M, et al.: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7(5):377-387, 2001.

140. Rosen LS, Gordon D, Kaminski M, et al.: Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, doubleblind, multicenter, comparative trial. Cancer 98(8): 1735-1744, 2003.

141. Fourney DR, Schomer DF, Nader R, et al.: Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients. J Neurosurg 98(suppl 1):21-30, 2003.

142. Lieberman I, Reinhardt MK: Vertebroplasty and kypho-plasty for osteolytic vertebral collapse. Clin Orthop (suppl 415):S176-S186, 2003.

143. Peters KR, Guiot BH, Martin PA, Fessler RG: Verte-broplasty for osteoporotic compression fractures: current practice and evolving techniques. Neurosurgery 51(suppl 5):96-103, 2002.

144. Hayek D, Ritschard J, Zwahlen A, Courvoisier B, Donath A: [Use of strontium-89 in the analgesic treatment of bone metastases]. Schweiz Med Wochenschr 110(31-32):1154-1159, 1980.

145. Pearse RN, Sordillo EM, Yaccoby S, et al.: Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A 98(20):11581-11586, 2001.

146. Body JJ, Greipp P, Coleman RE, et al.: A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97(suppl 3): 887-892, 2003.

147. Cazzola M, Messinger D, Battistel V, et al.: Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 86(12):4446-4453, 1995.

148. Dammacco F, Silvestris F, Castoldi GL, et al.: The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy. Int J Clin Lab Res 28(2):127-134, 1998.

149. Garton JP, Gertz MA, Witzig TE, et al.: Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, doubleblind trial. Arch Intern Med 155(19):2069-2074, 1995.

150. Osterborg A, Boogaerts MA, Cimino R, et al.: Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma—a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Blood 87(7):2675-2682, 1996.

151. Rizzo JD, Lichtin AE, Woolf SH, et al.: Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20(19):4083-4107, 2002.

152. Knight R, DeLap RJ, Zeldis JB: Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354(19):2079-2080, 2006.

153. Hedenus M, Adriansson M, San Miguel J, et al.: Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 122(3):394-403, 2003.

154. Kotasek D, Steger G, Faught W, et al.: Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 39(14):2026-2034, 2003.

155. Mirtsching B, Charu V, Vadhan-Raj S, et al.: Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis. Oncology (Huntingt) 16(suppl 11): 31-36, 2002.

156. Srkalovic G, Cameron MG, Rybicki L, Deitcher SR, Kattke-Marchant K, Hussein MA: Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothrom-boembolic disease. Cancer 101(3):558-566, 2004.

157. Rajkumar SV, Blood E: Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354(19):2079-2080, 2006.

158. Zonder JA, Barlogie B, Durie BG, McCoy J, Crowley J, Hussein MA: Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood 108(1):403, 2006.

159. Baz R, Li L, Kottke-Marchant K, et al.: The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 80(12):1568-1574, 2005.

160. Zonder JA, Barlogie B, Durie BG, McCoy J, Crowley J, Hussein MA: Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood 108(1):403, 2006.

161. Rajkumar SV: Thalidomide therapy and deep venous thrombosis in multiple myeloma. Mayo Clin Proc 80(12):1549-1551, 2005.

162. Corso A, Arcaini L, Caberlon S, et al.: A combination of dexamethasone, cyclophosphamide, etoposide, and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma. Haematologica 87(10): 1041-1045, 2002.

163. Palva IP, Ahrenberg P, Ala-Harja K, et al.: Treatment of multiple myeloma with an intensive 5-drug combina tion or intermittent melphalan and prednisone; a randomised multicentre trial. Finnish Leukaemia Group. Eur J Haematol 38(1):50-54, 1987.

164. Segeren CM, Sonneveld P, van der HB, et al.: Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br J Haematol 105(1):127-130, 1999.

Was this article helpful?

0 0

Post a comment